Nontricyclic antidepressants: Current trends in children and adolescents

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 38, Issue 5, 1999, Pages 517-528

  Emslie, Graham J ^a   Walkup, John T ^b   Pliszka, Steven R ^c   Ernst, Monique ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Efficacy; Monoamine oxidase inhibitors; Psychopharmacology; Safety; Selective serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; AMIFLAMINE; ANTIDEPRESSANT AGENT; BROFAROMINE; CIMOXATONE; CLOMIPRAMINE; DEXAMPHETAMINE; EUTRON; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; INCAZANE; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PARGYLINE; PAROXETINE; PHENELZINE; PIRLINDOLE; PLACEBO; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLOXATONE; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ADOLESCENT; ANXIETY NEUROSIS; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; INSOMNIA; MANIA; MENTAL DISEASE; MUTISM; OBSESSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 0032906439     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199905000-00013     Document Type: Article

References (118)

1. Adler LA, Resnick S, Kunz M, Devinsky O (1995), Open label trial ofvenlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 31:785-788
2. Alessi N, Bos T (1991), Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder (letter). Am J Psychiatry 148: 1605-1606
3. Alexander RC (1991), Fluoxetine treatment of trichotillomania (letter). J Clin Psychiatry 52:88
4. Alien AJ, Leonard H, Swedo SE (1995), Current knowledge of medications ' for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 34:976-986
5. Armitage R, Rush AJ, Trivedi M, Cain J, RoffWarg HP (1994), The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 10:123-127
6. Bakish D, Saxena BM, Bowen R, D'Souza J (1993), Reversible monoamine oxidase-A inhibitors in panic disorders. Clin Neuropharmacol 16(suppl 2):S77-S82
7. Ball SE, Ahern D, Scatina J, Kao J (1997), Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. BrJ Clin Prearmacol 43:619-626
8. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M (1991), Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762-767
9. Barrickman LL, Perry PJ, Alien AJ et al. (1995), Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649-657
10. Bass JN, Beltis J (1991), Therapeutic effect of fluoxetine on naltrexoneresistant self-injurious behavior in an adolescent with mental retardation. ] Child Adolesc Psychopharmacol 1:331-340
11. Bernstein GA, Burchardt CM, Perwien AR (1996), Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Arad Child Adolesc Psychiatry 35:1110-1119
12. Black B, UhdeTW (1992), Elective mutism as a variant of social phobia. J Am Acad Child Adolesc Psychiatry 31:1090-1094
13. Black B, UhdeTW, Tancer ME (1992), Fluoxetine for the treatment of social phobia. J Am Acad Child Adolesc Psychiatry 29:36-44
14. Boulos C, Kutcher S, Gardner D, Young E (1992), An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 2:103-111
15. Brophy B (1995), Kindergarteners in Prozac nation. US News and World Report November 13, pp 96-97
16. Buckingham D, Gaffney G (1993), NewTS treatment (letter). J Am Acad Child Adolesc Psychiatry 32:224
17. Cabrera TM, Battaglia G (1994), Delayed decreases in brain 5-hydroxytryptamine 2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J PharmacolExp The r 269:637-645
18. Casat CD, Pleasants DZ, Schroeder DH, Parler DW (1989), Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25: 198-201
19. Clay TH, Gualtieri CT, Evans RW, Guillion CM (1988), Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull 24:143-148
20. Como PG, Kurlan R (1991), An open-label trial of fluoxetine for obsessivecompulsive disorder in Gilles de la Tourette's syndrome. Neurology 41:872-874
21. Conners CK, Casat CD, Guitliera CT et al. (1996), Bupropion hydrochloride in attention deficit disorder with hyperactivity. JAm Acad Child Adolesc Psychiatry 35:1314-1321
22. Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL (1992), Fluoxetine treatment of children and adults with autistic disorder and mental retardation. JAm Acad Child Adolesc Psychiatry 31:739-745
23. Dahl RE, Puig-Antich J, Ryan ND et al. (1990), EEC sleep in adolescents with major depression: the role of suicidality and inpatient status. J Affect Disord 19:63-75
24. Da Prada M, Zurcher G, Wuthrich I, Haefely WE (1988), On tyramine, food, beverages, and the reversible MAO inhibitor moclobemide. J Neural Transm 26:31-56
25. Dech B, Budow L (1991), The use of fluoxetine in an adolescent with Prader- Willi syndrome. J Am Acad Child Adolesc Psychiatry 30:298-302
26. Derivan A, Aguiar L, Prcskorn S, Martin P, D'Amico D, Troy S (1995), A study of venlafaxine in children and adolescents with conduct disorder. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, p 128
27. DeVane CL (1994), Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55(suppl):38-47
28. DeVane CL, Sallee FR (1996), Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 57:55-66
29. Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keysor CS, Murphy DL (1989), Fenfluramine and dextroamphetamine treatment of childhood hyperactivity: clinical and biochemical findings. Arch Gen Psychiatry 46:205-212
30. Dummit ES III, Klein RG, Tancer NK, Asche B, Martin J (1996), Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 35:615-621
31. Emslie GJ, Rush AJ, Weinberg WA et al. (1997), Double-blind placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 54:1031-1037
32. Emslie GJ, Rush AJ, Weinberg WA, Rintelmann JW, Roflwarg HP (1990), Children with major depression show reduced rapid eye movement latencies. Arch Gen Psychiatry 47:119-124
33. Ernst M, Liebenauer LL, Jons PH, Tebeka D, Cohen RM, Zametkin AJ (1996), Selegiline in adults with attention deficit hyperactiviry disorder: clinical efficacy and safety. Psychopharmacol Bull 32:327-334
34. Fahlen T (1995), Personality traits in social phobia, II: changes during drug treatment. J Clin Psychiatry 56:569-573
35. Fawcett J, Marcus RN, Anton SJ, O'Brien K, Schwiderski U (1995), Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 56(suppl 6):37-42
36. Feierabend RH Jr (1995), Benign course in a child with a massive fluoxetine overdose. J Fam Pract 41:289-291
37. Findling RL, Schwartz MA, Flannery DJ, Manos MJ (1996), Venlafaxine in adults with attention-dcficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 57:184-189
38. Gammon GD, Brown TE (1993), Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J ChildAdolesc Psychopharmacol3:1-10
39. Geller B, Fox LW, Fletcher M (1993), Effect of tricyclic antidepressants on switching to mania and on the onset of bipolarity in depressed 6- to 12year-olds. J Am Acad Child Adolesc Psychiatry 32:43-50
40. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE (1995), Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36-44
41. Ghaziuddin M, Tsai L, Ghaziuddin N (1991), Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 30:508-509
42. Ghaziuddin N, Naylor MW, King CA (1995), Fluoxetine in tricyclic refractory depression in adolescents. Depression 2:287-291
43. Goldman-Rakic P, Brown RM (1982), Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Dev Brain Res 4:339-349
44. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G (1995), Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-458
45. Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH (1995), An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 31:779-783
46. Hilton S, Jaber B, Ruch R (1995), Moclobemide safety: monitoring a newly developed product in the 1990s. J Clin Psychopharmacol 15(suppl 2): S76-S83
47. Hindmarch I, Kerr J (1992), The behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 105(suppl): S49-S55
48. Hoagwood K, Jensen PS, Petti T, Burns BJ (1996), Outcomes of mental health care for children and adolescents, I: a comprehensive conceptual model. JAm Acad Child Adolesc Psychiatry 35:1055-1063
49. Hrdina PV, Thu BV (1993), Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5HT2 receptors in rat brain. Synapse 14:324-331
50. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N (1992), Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J ChildAdolesc Psychopharmacol 2:259-265
51. Jankovic J (1993), Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neural 50:286-288
52. Jefferson JW (1995), Social phobia: a pharmacologie treatment overview. J Clin Psychiatry 56(suppl 5): 18-24
53. Jensen PS, Hoagwood K, Petti T (1996), Outcomes of mental health care in children and adolescents, II: literature review and application of a comprehensive model. JAm Acad Child Adolesc Psychiatry 35:1065-1077
54. Jerome L (1991), Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry 30:850-851
55. rung BH (1991), Fluoxetine induced self-injurious behavior in an adolescent with mental retardation. J Child Adolesc Psychopharmacol 1:321-329
56. Kovacs M (1996), Presentation and course of major depressive disorder during childhood and later years of the life spun. J Am Acad Child Adolesc Psychiatry 35:705-715
57. Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP (1993), A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol 16:167-172
58. Kutcher S, Malkin D, Silverberg L et al. (1991), Nocturnal Cortisol, thyroid stimulating hormone, and growth hormone secretory profiles in depressed adolescents. JAm Acad Child Adolesc Psychiatry 30:407-414
59. Leonard BE (1996), The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Selective Serotonin ReUptake Inhibitors, 2nd ed. West Sussex, England: Wilcy, pp 35-62
60. Liebowitz MR, Hollander E, Fairbanks J, Campeas R (1990), Fluoxetine for adolescents with obsessive-compulsive disorder (letter). Am J Psychiatry 147:370-371
61. Liebowitz MR, Schneier F, Gitow A, Feerick J (1993), Reversible monoamine oxidase-A inhibitors in social phobia. Clin Netiropharmcol 16(suppl 2):83-88
62. Mallinger AG, Smith E (1991), Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 27:493-502
63. Mandoki MW, Tapia MR, Tapia MA, Summer GS, Parker JL (1997), Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149-154
64. Mann JJ, Aarons SF, Wilner PJ, Keilp J (1989), A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46:45-50
65. March JS, Leonard HL (1996), Obsessive-compulsive disorder in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:1265-1273
66. McCabe BJ (1986), Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am DietAssoc 86:1059-1064
67. McCann U, Hatzidimitriou G, Ridenow A et al. (1994), Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 269:792-798
68. McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K (1996), An open study of the effects of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 6:41-51
69. McCracken JT (1992), Etiological aspects of child and adolescent mood disorders. Child Adolesc Psychiatr Clin North Am 1:89-109
70. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008
71. McDougle CJ, Price LH, Goodman WK (1990), Fluvoxamine treatment of coincident autistic disorders and obsessive-compulsive disorder: a case report. J Autism Dev Disord 20:537-543
72. Mehlinger R, Scheftner WA, Poznanski E (1990), Fluoxetine and autism (letter). JAm Acad Child Adolesc Psychiatry 29:985
73. Montgomery SA (1993), Venlafaxinc: a new dimension in antidepressant pharmacology. J Clin Psychiatry 54:119-126
74. Motavalli N (1995), Fluoxetine for (s)elective mutism. J Am Acad Child Adolfsc Psychiatry 33:1000-1006
75. Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987), Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidcpressants and the psychobiology of the affective disorders and some related disorders. In: Psychopharmacology: The Third Centration of Progress, Meltzer HY, ed. New York: Raven, pp 545-552
76. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994), Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14:419-423
77. Nolen WA, Hafrmans PMJ, Bouvy PF, Duivenvoorden HJ (1993), Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 28:189-197
78. Olvera RL, Pliszka SR, Luh J, Tatum R (1996), An open trial of venlafaxine in the treatment of attention-deficitJhyperactivity disorder in children and adolescents. J ChildAdolesc Psychophannacol 6:241-250
79. Pato MT, Murphy DL, DeVane CL (1991), Sustained plasma concentrations of fluoxetine andJor norfluoxetine four to eight weeks after fluoxetine discontinuation. J Clin Psychofharmacol 11:224-225
80. Peet M (1994), Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164:549-550
81. Pine DS, Cohen P, Brook J (1996), Emotional problems during youth as predictors of stature during early adulthood: results from a prospective epidemiologic study. Pediatrics 97:856-863
82. Pliszka SR, McCracken JT, Maas JW (1996), Catecholamines in attentiondeficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272
83. Popper CW (1997), Antidepressants in the treatment of attention-deficitJ hyperactivity disorder.J Clin Psychiatry 58(suppl 14):14-31
84. Poznanski EO, Carroll BJ, Banegas MC, Cook SC, Grossman JA (1982), The dexamethasone suppression test in prepubertal depressed children. Am J Psychiatry 139:321-324
85. Preskorn SH (1995), Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56(suppl 6):12-21
86. Priest RG, Gimbrett R, Roberts M, Steinert J (1995), Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand Stiff1386:40-43
87. Puig-Antich J, Dahl R, Ryan N et al. (1989), Cortisol secretion in prepubertal children with major depressive disorder: episode and recovery. Arch Gen Psychiatry 46:801-809
88. Rapoport JL, Zametkin AJ, Donnelly M, Ismond D (1985), New drug trials in attention deficit disorder. Psychofharmacol Bull 21:232-235
89. Riddle MA, Brown N, Dzubinski D, Jetmalani AN, Law Y, Woolston JL (1989), Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 28:587-588
90. Riddle MA, Claghorn J, Gaffney G et al. (1996), Fluvoxamine for children and adolescents with obsessive compulsive disorder: a controlled multicenter trial. In: Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry XII, pp 110-111
91. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL (1990a), Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. JAm Acad Child Adolesc Psychiatry 29:45-48
92. Riddle MA, King RA, Hardin MT et al. (1990b), Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychofharmacol 1:193-198
93. Riddle MA, Scahill L, King RA et al. (1992), Double-blind trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062-1069
94. Ryan ND, Puig-Antich J, Rabinovich H et al. (1988), MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27:755-758
95. Salem B, Grunbcrger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G (1992), Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 33:589-601
96. Sheikha SH, Wagner KD, Wagner RJ Jr (1993), Fluoxetine treatment of trichotillomania and depression in a prepubertal child. Cutis 51:50-52
97. Simeon JG, Dinicola VF, Ferguson HB, Copping W (1990a), Adolescent depression: a placebo-controlled fluoxetine study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 14:791-795
98. Simeon JG, Ferguson HB, Van-Wyck-Fleet J (1986), Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 31:581-585
99. Simeon JG, Thatte S, Wiggins D (1990b), Treatment of adolescent obsessivecompulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 26:285-290
100. Streichenwein SM, Thornby JI (1995), A long-term, double-blind, placebocontrolled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 152:1192-1196
101. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985), Tyramine prcssor sensitivity changes during deprenyl treatment. Psychopharmacoloiy 86:432-437
102. Taylor DP, Carter RB, Eison AS et al. (1995), Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56(suppl 6):3-11
103. Thase ME (1996), Antidepressant options: venlafaxine in perspective.J Clin Pychopharmacol l6(suppl):105-205
104. Tierney E, Paramjit TJ, Llinas JF, Rosenberg LA, Riddle MA (1995), Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adoltsc Psychopharmacol 5:13-27
105. Todd RD (1991), Fluoxetine in autism (letter). Am J Psychiatry 148:1089
106. Travis GW, Emslie GJ, Orsulak P et al. (1993), Plasma fluoxetine levels in depressed children and adolescents. Biol Psychiatry 33:106A
107. Trott GE, Friese HJ, Menzel M, Nissen G (1992), Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 106(suppl):134-136
108. Van Vliet IM, den Boer JA, Westenberg HG, Slaap BR (1996), A double' blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 16:299-306
109. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, BuelkeSara J (1994), A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam AfflToxicol 23:194-205
110. Waldmeier PC (1993), Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Prog Nturopsychopharmacol Biol Psychiatry 17:183-198
111. Walkup JT (1994), A differential diagnosis of the adverse behavioral effects of fluoxetine. NewslAm Acad Child Adolesc Psychiatry 25 (3):28-30
112. Wender PH, Wood DR, Reimherr FW, Ward M (1983), An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 9:329-336
113. Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR (1989), The effects of moclobemide in cognition. J Neural Transm 28(suppl): S91-S102
114. Wilens TE, Spencer TJ, Biederman J, Schleifer D (1997), Case study: nefazodone for juvenile mood disorders. J Am Acad Child Adolesc Psychiatry 36:481-485
115. Wolkow R, March J, Safferman A, Biederman J (1997), A placebo-controlled trial of sertraline treatment for pediatrie obsessive compulsive disorder. Abstracted in the 6th World Congress of Biological Psychiatry, Nice, France, 42:2135
116. Wood DR, Reimherr FW, Wender PH (1983), The use of L-deprenyl in the treatment of attention deficit disorder, residual type. Psychopharmacol Bull 19:627-629
117. Youdim MB, Riederer P (1993), Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 91:181-195
118. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D (1985), Treatment of hyperactive children with monoamine oxidase inhibitors, I: clinical efficacy. Arch Gen Psychiatry 42:962-966